This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.
https://ift.tt/2QcfTGE
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου